Peer-reviewedCC BY-NC-NDHemaSphere
Chimeric antigen receptor T‐cell therapy as a cure for large B‐cell lymphoma
- 1University of Rochester Medical Center
- 2Newcastle Upon Tyne Hospitals NHS Foundation Trust
- 3Newcastle University
Related
- Baseline Spleen Volume is Independently Associated With Survival After CD19-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
- Lymphoma response to chimeric antigen receptor T cell therapy is driven by endogenous tumor-reactive CD8⁺ T cells
- A REAL-WORLD STUDY OF THE EFFECTIVENESS AND SAFETY OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOLLOWING TAFASITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
- Chimeric Antigen Receptor T-cell (CAR-T) Therapy in Autoimmune Diseases: A Narrative Review
- Immune Profiling after treatment with an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Treatment-Refractory Progressive Multiple Sclerosis
BibTeX
@article{wallace2026chimeric,
title = {{Chimeric antigen receptor T‐cell therapy as a cure for large B‐cell lymphoma}},
author = {Danielle S. Wallace and Yashashree Gupta and Carla Casulo and Wendy Osborne},
journal = {HemaSphere},
year = {2026},
month = nov,
url = {https://europepmc.org/article/PMC/PMC13730018},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Chimeric antigen receptor T‐cell therapy as a cure for large B‐cell lymphoma
AU - Danielle S. Wallace
AU - Yashashree Gupta
AU - Carla Casulo
AU - Wendy Osborne
PY - 2026
DA - 2026/11/01
JO - HemaSphere
UR - https://europepmc.org/article/PMC/PMC13730018
SN - 2572-9241
ER -